ES2284686T3 - Compuestos antitumorales triciclicos que son inhibidores de la proteina transferasa de farnesilo. - Google Patents

Compuestos antitumorales triciclicos que son inhibidores de la proteina transferasa de farnesilo. Download PDF

Info

Publication number
ES2284686T3
ES2284686T3 ES01968188T ES01968188T ES2284686T3 ES 2284686 T3 ES2284686 T3 ES 2284686T3 ES 01968188 T ES01968188 T ES 01968188T ES 01968188 T ES01968188 T ES 01968188T ES 2284686 T3 ES2284686 T3 ES 2284686T3
Authority
ES
Spain
Prior art keywords
compound
baselineskip
substituted
alkyl
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01968188T
Other languages
English (en)
Spanish (es)
Inventor
F. George Njoroge
Bancha Vibulbhan
Alan B. Cooper
Timothy Guzi
Dinanath F. Rane
Keith P. Minor
Ronald J. Doll
Viyyoor Moopil Girijavallabhan
Bama Santhanam
Patrick A. Pinto
Hugh Y. Zhu
Kartik M. Keertikar
Carmen S. Alvarez
John J. Baldwin
Ge Li
Chia-Yu Huang
Ray A. James
Robert W. Bishop
James Wang
Jagdish A. Desai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Pharmacopeia LLC
Original Assignee
Pharmacopeia Inc
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacopeia Inc, Schering Corp filed Critical Pharmacopeia Inc
Application granted granted Critical
Publication of ES2284686T3 publication Critical patent/ES2284686T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • C07D221/16Ring systems of three rings containing carbocyclic rings other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES01968188T 2000-08-30 2001-08-28 Compuestos antitumorales triciclicos que son inhibidores de la proteina transferasa de farnesilo. Expired - Lifetime ES2284686T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22918300P 2000-08-30 2000-08-30
US229183P 2000-08-30

Publications (1)

Publication Number Publication Date
ES2284686T3 true ES2284686T3 (es) 2007-11-16

Family

ID=22860141

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01968188T Expired - Lifetime ES2284686T3 (es) 2000-08-30 2001-08-28 Compuestos antitumorales triciclicos que son inhibidores de la proteina transferasa de farnesilo.

Country Status (27)

Country Link
US (1) US20020198216A1 (enExample)
EP (1) EP1313725B1 (enExample)
JP (1) JP2004513885A (enExample)
KR (1) KR20030034161A (enExample)
CN (1) CN100384837C (enExample)
AR (1) AR033680A1 (enExample)
AT (1) ATE359281T1 (enExample)
AU (2) AU8845101A (enExample)
BR (1) BR0113675A (enExample)
CA (1) CA2420673A1 (enExample)
CO (1) CO5640109A2 (enExample)
DE (1) DE60127846T2 (enExample)
EC (1) ECSP034494A (enExample)
ES (1) ES2284686T3 (enExample)
HK (1) HK1054548B (enExample)
HU (1) HUP0302942A3 (enExample)
IL (1) IL154528A0 (enExample)
MX (1) MXPA03001849A (enExample)
NO (1) NO20030918L (enExample)
NZ (1) NZ524246A (enExample)
PE (1) PE20020486A1 (enExample)
PL (1) PL361103A1 (enExample)
RU (1) RU2293734C9 (enExample)
SK (1) SK2292003A3 (enExample)
TW (1) TWI268280B (enExample)
WO (1) WO2002018368A1 (enExample)
ZA (1) ZA200301545B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
EE05417B1 (et) * 2001-03-14 2011-06-15 Bristol-Myers Squibb Company Epotilooni analoogide ja kemoterapeutikumide kombinatsiooni kasutamine teraapias
JP2005531488A (ja) * 2001-10-09 2005-10-20 ザ・ユニバーシティ・オブ・シンシナティ 甲状腺癌を処置するためのegf受容体阻害剤
EP1448268A2 (en) * 2001-11-30 2004-08-25 Schering Corporation Use of an farnesyl protein transferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
JP2005515201A (ja) * 2001-12-03 2005-05-26 シェーリング コーポレイション 癌の処置におけるfptインヒビターおよび少なくとも2つの抗腫瘍性剤の使用
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
EP1606285A4 (en) * 2003-03-27 2009-03-18 Lankenau Inst Medical Res NEW IDO HEMMER AND APPLICATION PROCEDURES
EP1628631A2 (en) * 2003-06-05 2006-03-01 Achkar, Charles C. Methods of treating hyperproliferative cell disorders
BRPI0411250A (pt) * 2003-06-09 2006-08-29 Samuel Waksal método de inibição de receptor tirosina cinase com um antagonista extracelular e um antagonista intracellular
ES2235611B2 (es) * 2003-07-25 2006-07-16 Universidade De Santiago De Compostela Metodo cuantitativo para la deteccion de yesotoxinas en productos pesqueros basado en la activacion que producen en las fosfodiesterasas.
BRPI0413384A (pt) * 2003-08-07 2006-10-17 Schering Corp inibidores da proteìna farnesil transferase como agentes antitumores
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
MY138124A (en) * 2004-12-21 2009-04-30 Schering Corp Novel farnesyl protein transferase inhibitors as antitumor agents
RU2361587C1 (ru) * 2008-02-14 2009-07-20 Михаил Владимирович Кутушов Лекарственное средство для лечения онкологических заболеваний
CA2730190A1 (en) * 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
WO2020258211A1 (en) * 2019-06-28 2020-12-30 Anhui Ronghang Biotech Development Co., Ltd. Compositions and methods for treatment of hepatitis b virus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
IL98572A (en) * 1990-06-22 1995-07-31 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene, piperidylidene and piperazine compositions an methods of use
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
US5925648A (en) * 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
CA2354774C (en) * 1998-12-18 2009-05-26 Schering Corporation Farnesyl protein transferase inhibitors

Also Published As

Publication number Publication date
AU2001288451C1 (en) 2008-03-06
US20020198216A1 (en) 2002-12-26
NO20030918L (no) 2003-04-29
IL154528A0 (en) 2003-09-17
AU2001288451B2 (en) 2007-05-24
ZA200301545B (en) 2004-06-22
TWI268280B (en) 2006-12-11
DE60127846T2 (de) 2008-03-06
PE20020486A1 (es) 2002-06-14
BR0113675A (pt) 2003-06-24
RU2293734C2 (ru) 2007-02-20
NO20030918D0 (no) 2003-02-27
PL361103A1 (en) 2004-09-20
ATE359281T1 (de) 2007-05-15
MXPA03001849A (es) 2003-06-04
KR20030034161A (ko) 2003-05-01
HK1054548A1 (en) 2003-12-05
HUP0302942A3 (en) 2007-02-28
EP1313725A1 (en) 2003-05-28
EP1313725B1 (en) 2007-04-11
RU2293734C9 (ru) 2007-10-10
CN100384837C (zh) 2008-04-30
CA2420673A1 (en) 2002-03-07
CO5640109A2 (es) 2006-05-31
NZ524246A (en) 2004-11-26
DE60127846D1 (en) 2007-05-24
SK2292003A3 (en) 2003-08-05
AU8845101A (en) 2002-03-13
ECSP034494A (es) 2003-04-25
HUP0302942A2 (hu) 2003-12-29
HK1054548B (en) 2007-10-18
WO2002018368A1 (en) 2002-03-07
CN1471524A (zh) 2004-01-28
AR033680A1 (es) 2004-01-07
JP2004513885A (ja) 2004-05-13

Similar Documents

Publication Publication Date Title
ES2284686T3 (es) Compuestos antitumorales triciclicos que son inhibidores de la proteina transferasa de farnesilo.
CN109153675A (zh) 细胞周期蛋白依赖性激酶9(cdk9)通过cdk9抑制剂与e3连接酶配体的缀合的降解及使用方法
US20030229099A1 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
US20040006087A1 (en) Method of treating cancer using FPT inhibitors and antineoplastic agents
AU2001288451A1 (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
HUE029370T2 (hu) Rákellenes aktivitású vegyületek
US7342016B2 (en) Farnesyl protein transferase inhibitors as antitumor agents
ES2869229T3 (es) Derivados de 2-(((pirrolidin-3-il)carbonil)amino)-1H-imidazol como agonistas del receptor de melanocortina 1 (MCR1) para tratar la artritis reumatoide
ES2347643T3 (es) Piperin- y piperazinacetamidas como inhibidores de 17beta hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades dependientes de androgenos.
TW200536539A (en) Organic compounds
EP0989983B1 (en) Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase
JP2005525356A5 (enExample)
TW382016B (en) 4-[(thien-2yl)methyl]-imidazole analgesics
ES2313626T3 (es) Derivados de triazol sustituidos como antagonistas de oxitocina.
AU2007202115A1 (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
WO2023225327A1 (en) Inducers of integrated stress response to treat cancer
CA2816804A1 (en) Substituted bicyclic carboxamide and urea derivatives as vanilloid receptor ligands
MXPA01006241A (en) Tricyclic farnesyl protein transferase inhibitors